Follow us on:

Linkedin Facebook

September 29, 2025

Fidelity European Trust

Pharma shifts and tech resilience shape a new mood in European equities

European stocks are catching lift from pharma reshuffles and tech rebounds even as Lufthansa’s bold cost cuts raise the stakes for execution...
KEFI

Copper market edges towards a strategic inflection

Tighter supply and resilient demand are reinforcing copper’s role as a strategic pillar of global growth and investor opportunity...
Fidelity

FTSE share prices climb as healthcare momentum meets US data focus

Momentum in UK healthcare stocks is reshaping the FTSE’s profile just as US jobs data becomes the next major inflection point...
General Helium Inc

Helium and its pivotal role in critical industries

Helium’s scarcity and irreplaceability in cryogenics make it one of the few industrial gases where supply risk can become a strategic concern...
Fidelity

Asia steadies as investors navigate policy shifts and US uncertainty

Asia steadies as technology strength offsets global uncertainty while investors await key central bank signals...
Dekel Agri-Vision

Palm oil finds fresh momentum amid energy and trade shifts

Palm oil futures are staging a modest rebound, hinting at deeper structural shifts linking energy price moves, seasonal demand, and export policy shifts...
Thor Energy

Thor Energy highlights strategic pivot to hydrogen and helium in 2025 Annual Results

Thor Energy has reported audited results for the year ended 30 June 2025, marking a major strategic shift to natural hydrogen and helium exploration in South Australia...
Cora Gold Ltd

Gold’s new threshold suggests a shift in risk appetite

Gold’s push past $3,800/oz signals shifting assumptions about central banks and risk...
Fidelity China Special Situations

Signs of a subtle shift in China’s market mood

China’s rally now speaks less of stimulus and more of a change in the rules, from low-price warfare to disciplined profitability...
Broker Ratings

Sarepta Therapeutics, Inc. (SRPT): Investor Outlook with a 24.59% Potential Upside

Broker Ratings

TransMedics Group, Inc. (TMDX) Stock Analysis: A 23% Upside Potential in the Innovative Organ Transplant Sector

Broker Ratings

iRhythm Technologies, Inc. (IRTC) Stock Analysis: 26% Revenue Growth and Promising Upside

Broker Ratings

Avidity Biosciences, Inc. (RNA) Stock Analysis: A Promising Biotech Play with 58.58% Potential Upside

Broker Ratings

Krystal Biotech, Inc. (KRYS) Stock Analysis: Uncovering a 22% Upside Potential Amidst Robust Revenue Growth

Broker Ratings

Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Exploring an 18.64% Potential Upside in the Rare Disease Biotech Space

Broker Ratings

Charles River Laboratories (CRL) Stock Analysis: Navigating Market Volatility with a 19.64% Potential Upside

Broker Ratings

Cytokinetics, Incorporated (CYTK): Biotech Stock with 48% Upside Potential and Robust Revenue Growth

Broker Ratings

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring an 82.77% Potential Upside in the Biotech Sector

Broker Ratings

TG Therapeutics, Inc. (TGTX) Investor Outlook: Strong Revenue Growth and Promising Pipeline Signal Potential Upside

Broker Ratings

ADMA Biologics Inc (ADMA) Stock Analysis: A Promising 86.16% Upside in the Biotech Sector

Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

September 29, 2025

Fidelity European Trust

Pharma shifts and tech resilience shape a new mood in European equities

European stocks are catching lift from pharma reshuffles and tech rebounds even as Lufthansa’s bold cost cuts raise the stakes for execution...
KEFI

Copper market edges towards a strategic inflection

Tighter supply and resilient demand are reinforcing copper’s role as a strategic pillar of global growth and investor opportunity...
Fidelity

FTSE share prices climb as healthcare momentum meets US data focus

Momentum in UK healthcare stocks is reshaping the FTSE’s profile just as US jobs data becomes the next major inflection point...
General Helium Inc

Helium and its pivotal role in critical industries

Helium’s scarcity and irreplaceability in cryogenics make it one of the few industrial gases where supply risk can become a strategic concern...
Fidelity

Asia steadies as investors navigate policy shifts and US uncertainty

Asia steadies as technology strength offsets global uncertainty while investors await key central bank signals...
Dekel Agri-Vision

Palm oil finds fresh momentum amid energy and trade shifts

Palm oil futures are staging a modest rebound, hinting at deeper structural shifts linking energy price moves, seasonal demand, and export policy shifts...
Thor Energy

Thor Energy highlights strategic pivot to hydrogen and helium in 2025 Annual Results

Thor Energy has reported audited results for the year ended 30 June 2025, marking a major strategic shift to natural hydrogen and helium exploration in South Australia...
Cora Gold Ltd

Gold’s new threshold suggests a shift in risk appetite

Gold’s push past $3,800/oz signals shifting assumptions about central banks and risk...
Fidelity China Special Situations

Signs of a subtle shift in China’s market mood

China’s rally now speaks less of stimulus and more of a change in the rules, from low-price warfare to disciplined profitability...
Broker Ratings

Sarepta Therapeutics, Inc. (SRPT): Investor Outlook with a 24.59% Potential Upside

Broker Ratings

TransMedics Group, Inc. (TMDX) Stock Analysis: A 23% Upside Potential in the Innovative Organ Transplant Sector

Broker Ratings

iRhythm Technologies, Inc. (IRTC) Stock Analysis: 26% Revenue Growth and Promising Upside

Broker Ratings

Avidity Biosciences, Inc. (RNA) Stock Analysis: A Promising Biotech Play with 58.58% Potential Upside

Broker Ratings

Krystal Biotech, Inc. (KRYS) Stock Analysis: Uncovering a 22% Upside Potential Amidst Robust Revenue Growth

Broker Ratings

Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Exploring an 18.64% Potential Upside in the Rare Disease Biotech Space

Broker Ratings

Charles River Laboratories (CRL) Stock Analysis: Navigating Market Volatility with a 19.64% Potential Upside

Broker Ratings

Cytokinetics, Incorporated (CYTK): Biotech Stock with 48% Upside Potential and Robust Revenue Growth

Broker Ratings

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring an 82.77% Potential Upside in the Biotech Sector

Broker Ratings

TG Therapeutics, Inc. (TGTX) Investor Outlook: Strong Revenue Growth and Promising Pipeline Signal Potential Upside

Broker Ratings

ADMA Biologics Inc (ADMA) Stock Analysis: A Promising 86.16% Upside in the Biotech Sector

Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

September 29, 2025

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple